Eli Lilly and Company has acquired preclinical biotechnology company Engage Biologics Inc. in a deal worth up to $202 million, strengthening the drugmaker’s ambitions in next-generation genetic medicines and non-viral DNA delivery technologies.
The acquisition gives Lilly access to Engage’s proprietary Tethosome platform, a preclinical technology designed to address longstanding challenges in DNA-based therapeutics, including delivery efficiency, tolerability, potency, and the ability to administer repeat doses. Financial terms disclosed by the companies indicate the transaction includes an upfront cash payment along with milestone-based payments tied to future development achievements.
According to the announcement, Lilly will pay up to $202 million in cash under the agreement, including immediate compensation and additional payments contingent upon the successful achievement of specified development milestones.
Engage, a biotechnology startup focused on advancing non-viral approaches to genetic medicine, has been developing the Tethosome platform as a novel delivery system aimed at improving how therapeutic DNA is introduced and expressed in the body. Unlike viral delivery systems, which can face limitations related to immune response, scalability, and repeat administration, Engage’s platform is designed to use lipid nanoparticles and messenger RNA (mRNA)-enabled technologies to improve precision and durability.
The Tethosome system combines engineered DNA payloads with lipid nanoparticle delivery and a proprietary mRNA-encoded technology intended to improve localization and increase gene expression. The platform also seeks to maintain key benefits associated with DNA-based therapies—such as durability and programmability—while minimizing tolerability concerns that have historically challenged the broader field of genetic medicine.
By integrating engineered DNA payloads with advanced delivery methods, Engage has aimed to create a therapeutic platform capable of supporting a new class of programmable medicines with the potential to address a range of diseases requiring long-term or repeat treatment.
Will Olsen, co-founder and chief executive officer of Engage, described the acquisition as a significant milestone for the startup, highlighting the company’s rapid progress despite operating with a lean team and modest seed funding.
Olsen said Engage’s achievements demonstrated how small biotechnology companies can rapidly innovate using advances in synthetic biology. He added that Lilly’s resources, operational speed, and strategic focus on genetic medicine make the pharmaceutical company a suitable partner to accelerate development of therapies based on the Tethosome platform.
The deal also underscores Lilly’s growing interest in expanding its capabilities beyond traditional therapeutics into emerging areas such as genetic medicine, RNA technologies, and advanced delivery systems. Pharmaceutical companies have increasingly pursued acquisitions and partnerships in this space as the industry seeks to unlock the therapeutic potential of DNA- and RNA-based approaches for chronic and rare diseases.
Although Engage remains in the preclinical stage, the acquisition provides Lilly with access to an early but potentially transformative platform that could be adapted for multiple therapeutic applications over time.
Legal counsel for Engage in the transaction was provided by Cooley LLP.
The acquisition reflects continued momentum in biotechnology dealmaking as large pharmaceutical companies seek to strengthen innovation pipelines through targeted acquisitions of emerging platform technologies that could support future generations of precision and genetic medicines.